Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy
A legfontosabb adatok
- Hol
- Aalborg, Herlev és Odense (Dánia)Mind a 3 helyszín megnézése
AI-kivonat: kiket keres a vizsgálat
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan felnőtteket keres, akik agyi áttét, gerincáttét, fej-nyaki daganat vagy tüdőrák miatt sugárkezelésre várnak. A kétenergiás CT-t hasonlítja az MRI-vizsgálathoz a daganatok körvonalazásában.
- Életkor
- 18 éves vagy idősebb
- Nem
- Nemtől függetlenül részt vehet.
- A betegség stádiuma
- Agyi áttét: 1-5 agyi áttét. Csontáttét: gerincáttét csontvelői érintettség nélkül. Fej-nyaki daganat: a diagnózis idején készült PET/CT-vizsgálat. Tüdőrák: csak legfeljebb 10 frakciós palliatív sugárkezelés.
- Korábbi kezelés
- Ugyanazon a területen, amelyre most sugárkezelést kapnak, nem volt korábban sugárkezelés vagy műtét.
A részvétel fő kizáró okai
- Terhesség
- Korábbi sugárkezelés vagy műtét ugyanazon a testtájon
- Allergia vagy más ok, amiatt nem kaphatják meg a vizsgálatokhoz szükséges kontrasztanyagot
- MRI-vizsgálatot kizáró ok, például pacemaker vagy nem MRI-kompatibilis implantátum
- Nem érti meg a betegtájékoztatót
Gépi kiolvasás: 2026. november 12.
Helyszínek itt: Dánia
- Aalborg University HospitalAalborg, DániaContact: Hella MB Sand, Medical Physicist, MScRésztvevőt keres
- Copenhagen University Hospital Herlev and GentofteHerlev, DániaContact: Jens Edmund, Medical Physicist, MSc, PhDToborzás még nem indult
- Odense University HospitalOdense, DániaContact: Tine Schytte, Clinical Oncologist, MD, PhDRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Aalborg University Hospital
- Azonosító
- NCT07185958
- A regiszteradat frissítve
- 2026. október 29.
- Eredeti leírás
The primary aim of this clinical study, 'Dual Energy CT - a tool for delineation of tumor and organs at risk in radiotherapy' (DART) is to evaluate whether dual-energy CT (DECT) is at least as effective as magnetic resonance imaging (MRI) in delineating both tumors and organs at risk (OARs) in patients referred for radiotherapy (RT). This primary aim will be explored in patient groups where the performance of DECT for RT has been described in the literature (but mostly based on signal-to-noise ratio and/or contrast-to-noise ratio), such as brain metastases (sub-cohort 'DART Brain') and head and neck cancer (sub-cohort 'DART H\&N'). Additionally, DART will explore diagnoses not yet studied in the literature, such as bone metastases (sub-cohort 'DART Bone'). If DECT could be demonstrated to achieve delineations for RT in both tumors and OARs that are equally accurate as those based on MRI, it could offer significant advantages by being faster and more cost-effective, making DECT a valuable alternative to MRI in clinical practice. As a secondary aim, the study will evaluate whether DART offers benefits when added to standard RT imaging for tumor and OAR delineation: (1) For lung cancer patients (sub-cohort 'DART Lung'), where MRI scans are typically not valuable due to tumor motion caused by breathing, 'DART Lung' will assess whether DECT performed in breath-hold provides added value compared to the single-energy CT (SECT) scan conducted during free breathing, as used in current clinical practice. (2) For head and neck cancer patients, 'DART H\&N' will evaluate whether DECT offers added value compared to the positron emission tomography (PET)/CT scan currently used in clinical practice.A teljes eredeti leírásKevesebb
The primary aim of this clinical study, 'Dual Energy CT - a tool for delineation of tumor and organs at risk in radiotherapy' (DART) is to evaluate whether dual-energy CT (DECT) is at least as effective as magnetic resonance imaging (MRI) in delineating both tumors and organs at risk (OARs) in patients referred for radiotherapy (RT). This primary aim will be explored in patient groups where the performance of DECT for RT has been described in the literature (but mostly based on signal-to-noise ratio and/or contrast-to-noise ratio), such as brain metastases (sub-cohort 'DART Brain') and head and neck cancer (sub-cohort 'DART H\&N'). Additionally, DART will explore diagnoses not yet studied in the literature, such as bone metastases (sub-cohort 'DART Bone'). If DECT could be demonstrated to achieve delineations for RT in both tumors and OARs that are equally accurate as those based on MRI, it could offer significant advantages by being faster and more cost-effective, making DECT a valuable alternative to MRI in clinical practice. As a secondary aim, the study will evaluate whether DART offers benefits when added to standard RT imaging for tumor and OAR delineation: (1) For lung cancer patients (sub-cohort 'DART Lung'), where MRI scans are typically not valuable due to tumor motion caused by breathing, 'DART Lung' will assess whether DECT performed in breath-hold provides added value compared to the single-energy CT (SECT) scan conducted during free breathing, as used in current clinical practice. (2) For head and neck cancer patients, 'DART H\&N' will evaluate whether DECT offers added value compared to the positron emission tomography (PET)/CT scan currently used in clinical practice.
Bevonási feltételek: Age ≥18 years; ECOG performance status (PS) 0-2; Assessed to be able to complete the protocol scanning regime; Referred for RT; Signed informed consent; For patients with brain metastasis (cohort A): 1-5 brain metastases referred for ei-ther whole brain or stereotactic RT; For patients with bone metastasis (cohort B): Metastases in one or more regions of the vertebral column (C1-C7, Th1-12, L1-L5, Os Sacrum), without medullary involve-ment, referred for either palliative or stereotactic RT; For head and neck cancer patients (cohort C): A PET/CT scan must have been per-formed during the diagnostic evaluation for cancer; For lung cancer patients (cohort D): Only patients referred for palliative RT with a maximum of 10 fractions.
Kizáró feltételek: Previous RT in the same anatomical area now referred for RT; Previous surgery in the same anatomical area now referred for RT; If relevant for the protocol scanning regime: Contraindication for MRI (pacemaker, metal, non-MRI, compatible implants etc.); If relevant for the protocol scanning regime: Allergic to contrast agent; Pregnancy; Participation in conflicting protocols; If relevant for the protocol scanning regime: Contraindication to iodine-based contrast agent for CT (as determined by the physician); If relevant for the protocol scanning regime: Contraindication to Gadolinium-based contrast agent for MRI (as determined by the physician); Incapable of understanding the patient information.